Bupropion HCL ER
Awarded Award Notice Posted
- Solicitation number
- SPE2D2-23-D-0002
- Agency
- Medical Supply Chain Troop Support, Department of Defense
- Awarded
- to Radha Pharmaceuticals Inc.
- Set-aside
- No set-aside
Opportunity facts
- Contract number
- SPE2D2-23-D-0002-SPE2D2-23-D-0002 Federal IDV award
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Place of performance
- Hauppauge, New York 11788, United States
- Points of contact
-
- Kyle Lewicki kyle.lewicki@dla.mil (445) 737-0977
- Jason Wray jason.wray@dla.mil (445) 737-6304
Notice details come from SAM.gov. Updated .
About this opportunity
The Defense Logistics Agency Troop Support Medical Supply Chain awarded contract SPE2D2-23-D-0002 to Radha Pharmaceuticals Inc. for Bupropion HCL ER on October 6, 2022, with an award value of $23,278,523.95.
The contract was awarded under unrestricted competition (no set-aside used). Place of performance is Hauppauge, New York, with contracting administration in Philadelphia, Pennsylvania. The contract includes four option years, each exercisable for one-year periods. Modification P00010, executed September 14, 2026, exercised Option Year 4 for the period October 6, 2026 through October 5, 2027. Prior modifications exercised Option Year 2 (effective October 6, 2024 through October 5, 2025), Option Year 3 (effective October 6, 2025 through October 5, 2026), and incorporated FAR 52.204-30 (Federal Acquisition Supply Chain Security Act Orders). Modification P00007, effective April 22, 2025, implemented DoD Class Deviations 2025-O0003 and 2025-O0004, which revised sustainability and equal employment opportunity requirements. Modification P00009 incorporated FAR 52.222-90 (Addressing DEI Discrimination by Federal Contractors, DEVIATION 2026-O0040, REVISION 1, effective April 2026). Contracting Officer Jason C. Wray administers the contract.
Notice text
2 versions
Update #2 · Latest ·
Modification P00010 SPE2D223D0002 is issued to invoke option year 4 for Bupropion HCL ER National Contract.
Modification P00009 SPE2D223D0002 is issued to incorporate clause 52.222-90, Addressing DEI Discrimination by Federal Contractors (DEVIATION 2026-O0040, REVISION 1) (APR 2026).
Modification P00008 SPE2D223D0002 is issued to invoke option year 3 for Bupropion HCL ER National Contract.
Modification P00007 SPE2D223D0002 is issued in accordance with DoD Class Deviation 2025-O0003 and Class Deviation 2025-O0004 into subject solicitation.
Modification P00006 SPE2D223D0002 is issued to invoke option year 2 for Bupropion HCL ER National Contract.
Modification P00005 SPE2D223D0002 is issued to incorporate FAR 52.204-30 Federal Acquisition Supply Chain Security Act Orders into subject solicitation.
NATIONAL CONTRACT SPE2D2-23-D-0002 BUPROPION HCL ER
Awarded contract SPE2D2-23-D-0002 to RADHA PHARMACEUTICALS INC for 23278523.95 on 2022-10-06.
Update #1 ·
NATIONAL CONTRACT SPE2D2-23-D-0002 BUPROPION HCL ER
Awarded contract SPE2D2-23-D-0002 to RADHA PHARMACEUTICALS INC for 23278523.95 on 2022-10-06.
Attachments
Show all 11
Notice history
| Notice | Type | Posted |
|---|---|---|
| Bupropion HCL ER | Award Notice | |
| Bupropion HCL ER | Solicitation | |
| Bupropion HCL ER | Pre-Solicitation |
On GovTribe
Work this opportunity on GovTribe
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity